Aptamers Market

Global Aptamers Market Size (2022 to 2027)

The global aptamers market size is estimated to grow from USD 242.3 million in 2022 to USD 523.5 million by 2027, progressing at a CAGR of 16.66 % during the forecast period.

Global Aptamers Market Share Insights:

• Based on type, the nucleic acid segment led the market and captured 69.4% of the global market share in 2021.
• North America dominated the market and held 42.6% of the global market share in 2021.
• The European region had a substantial share of the worldwide market in 2021 and is expected to be worth USD 130 million by 2027.
• The Asia-Pacific region captured a considerable share of the global market in 2021 and is anticipated to grow at a CAGR of 22.5% from 2022 to 2027.

The launch of Macugen, the first aptamer drug and the first diagnostic test for testing mycotoxins in grains, has recognized the potential of aptamers in diagnostics and therapeutics. As a result, the global market for aptamers is expected to grow, backed by technological advancements concerning selection processes and synthesis.

MARKET DRIVERS:

The growing adoption of technological advancements and increasing investments in R&D by the pharmaceutical and biotechnology industries are propelling the aptamers market growth.

Low cost and high efficacy in binding to large molecules compared to antibodies and the patent expiration of systematic evolution of ligands by exponential enrichment technology (SELEX) boost the aptamers market. In addition, factors such as betterments in the development technologies of aptamers and growing investments for R&D by the key market players to develop and produce recombinant products are supporting the global aptamers market. Furthermore, the growing use of aptamers in drug discoveries and treating various diseases further enhance the market's growth rate.

In addition, the growing prevalence of chronic diseases, increasing support from various governments to conduct R&D around aptamers, and increasing usage of aptamers in various applications are anticipated to result in the growth rate of the global aptamers market.

Furthermore, growing FDA approvals for aptamers are fuelling the market expansion. Growing awareness among manufacturers and encouraging pipeline, fewer costs associated with the aptamers growing R&D investments towards biotechnology and pharmaceutical sectors favor the aptamers market growth. The growing adoption of aptamers in chemical and food industries and increasing demand among the public due to their benefits, such as their high efficiency and low cost compared to antibodies, are further expected to drive the global aptamers market.

MARKET RESTRAINTS:

Stringent regulations in the use of aptamers, ethical issues of the aptamers obtained from the animals, and slow in reaching the marketplace due to regulatory hurdles, hinder the growth of the aptamers market.

In addition, the Lack of proper guidelines on molecular development, the shortage of trained and expert professionals, and low adoption rates are anticipated to restrict the market's growth rate. Low awareness about the latest technologies in middle and low-income countries and insufficient regulatory structure impedes growth globally. Furthermore, many aptamers have failed to meet the required safety and efficiency standards over clinical studies during the forecast period. Unfavorable characteristics of the aptamers obstruct growth.

Impact of COVID-19 on the global aptamers market:

As COVID-19, which SARS-CoV-2 causes, continues to infect millions of people worldwide, the race to develop new diagnoses, treatments, and preventive measures is more important than ever. As a result, a framework of diagnostics, treatments, and, most critically, vaccinations is being developed to build a complete management regimen.

Aptamer, a single-stranded folded RNA or DNA that can bind and detect different nucleic and non-nucleic acid compounds with great affinity and specificity, is one of the new DNA receptors. In recent years, the use of aptamer probes for viral detection has grown. Aptamers, multipotent biological probes, might be great for developing sensitive and specific biosensors. Although just a few types of research have focused on specific coronavirus aptamer types, they may aid in determining the optimal method for obtaining aptamers for this virus. In addition, any viral infection sign, including viral genes, proteins, and antibodies, might be detected using aptamers. Aptamers may be beneficial in this pandemic because they may be used to screen for and treat COVID-19, which is particularly beneficial given the limitations of existing techniques due to resource and equipment availability. Considering the factors above, the global aptamers market is expected to showcase healthy growth during the forecast period.

REPORT COVERAGE:

This research report on the global aptamers market has been segmented and sub-segmented based on the type, application, end-user, and region.

Aptamers Market - By Type:

• Peptide Aptamers
• Nucleic Acid Aptamers
  • DNA-Based Aptamers
  • RNA-Based Aptamers
  • XNA-Based Aptamers

Based on type, the nucleic acid segment accounted for the most significant share of the global aptamers market in 2021. At the same time, the nucleic acid segment is estimated to register a promising CAGR during the forecast period. The growing investments from market participants in nucleic acid aptamers to treat various diseases is one of the major factors promoting the segment's growth. Under this segment, the DNA-based aptamers sub-segment is anticipated to register dominance during the forecast period, and the growth of the segment is likely to grow at a great pace during the forecast period due to increasing research and development initiatives on DNA-based aptamers.

On the other hand, the peptide aptamers segment is estimated to grow at a healthy CAGR during the forecast period. This is because the usage of peptide aptamers is high in the diagnostics industry, primarily driving the segment's growth. 

Aptamers Market - By Application:

• Therapeutics Development
• Diagnostics
• Research and Development

Based on the application, the diagnostic segment contributed a significant share of the global market in 2021 and is anticipated to grow rapidly due to a continually increasing population with various diseases leading to a boost in demand for different diagnostic techniques.

Aptamers Market - By End User:

• Pharmaceutical Companies
• Bio-Pharmaceutical companies
• Academic and Research Centres

Based on end-user, the academic and research institutes segment has contributed significantly in recent years. Moreover, it is likely to grow further during the forecast period. The demand for aptamers from academic and research centers is growing continuously, which is expected to favor the segment's growth rate during the forecast period. In addition, the growing research activities on aptamers from the academic and research centers are further propelling the segment's growth. 

Aptamers Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regionally, North America dominates the global aptamers market with the highest share, followed by Europe Asia - Pacific. However, Asia-Pacific is expected to account for the highest growth during the forecast period. The North American aptamers market was the leader in the global market in 2021 and is expected to continue growing throughout the forecast period. This region is strongly driven by factors such as advancements in technology and increasing R&D activities. In addition, the United States is playing a leading role in the North American market due to favorable government initiatives and a rising number of research laboratories.

The aptamers market in the European region was ranked as the second-largest region in the global market in 2021. The increasing number of approvals for existing advanced technologies, the rising occurrence rate of chronic diseases, and the growing demand for therapies of aptamers in Europe actively support market growth. As a result, it is likely to be at the forefront and advanced within a short period in the forthcoming years. This region's growth is attributed to increasing approvals for existing advanced technologies, increasing incidence of chronic diseases, and growing demand for therapies of aptamers of this region.

APAC is expected to grow at the fastest CAGR among all regions worldwide during the forecast period. The growth of the aptamers market in the Asia-Pacific market is primarily driven by the efforts of the key market players of the developed regions to push into untapped markets. In addition, the growing R&D investments in the pharmaceutical and biotechnology industries are driving the APAC aptamers market growth during the forecast period. Furthermore, factors such as combined efforts taken by the key players of the developed regions to push into untapped markets fuelling the market. Increasing research and development investments in the pharmaceutical and biotechnology industries also bolsters the aptamers market growth during the forecast period.

The aptamers market in the Latin American region is likely to have a stable growth rate during the forecast period. Latin American growth is expected to drive by the improvements in aptamer development technologies; many companies are investing in this market and are accelerating the market. However, these aptamers have failed to meet the needs of protected and efficient standards in market clinical studies.

The aptamers market in the Middle East & Africa region is anticipated to have significant shares due to technological advancements. However, strict regulations for aptamers' usage and ethical issues for aptamers hamper the market growth in this region.

KEY MARKET PLAYERS:

Companies that are playing a leading role in the global aptamers market profiled in the report are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd, Aptus Biotech S.L, Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc., TriLink BioTechnologies Inc., and Vivonics, Inc.

NOTABLE HAPPENINGS IN THIS MARKET:

• In February 2019, Base Pair Biotechnologies Inc. developed point-of-care tests to diagnose neonatal abstinence syndrome based on aptamer with the SBIR grant's assistance. 
• In January 2019, Aptamer Group announced that the AstraZeneca Company has agreed to collaborate to expand the aptamer technology application potential. With this collaboration, AstraZeneca will adapt to the aptamer group's technology to improve the advanced drug delivery vehicles named after Aptamer Drug Conjugates (ApDCs).